Cumulus Neuroscience Secures £3.25m for Commercialization of Brain Tech
Deal News | Jul 08, 2025 | UK Tech Funding
Cumulus Neuroscience, a Belfast-based health tech company, has successfully closed a £3.25 million investment round aimed at commercializing its advanced brain assessment technology. The core product, an innovative EEG headset, is designed to rapidly collect and analyze brain data, offering significant advantages over traditional assessment methods. The firm's technology enables biopharma partners to gather objective data crucial for therapeutic research. This fresh capital injection will primarily be used to expand the company’s sales and marketing teams. The investment round was spearheaded by Whiterock, with additional support from the Investment Fund for Northern Ireland, Clarendon, ACF Investors, and Co-Fund NI. The company, currently employing 31 staff members across Belfast and Dublin, is poised for growth as it collaborates with leading global pharma and biotech companies.
Sectors
- Health Tech
- Biopharmaceuticals
Geography
- United Kingdom – Cumulus Neuroscience is based in Belfast, UK, and has operations in Dublin, which is relevant as the investment impacts the UK healthcare and technology markets.
- Ireland – The company's presence in Dublin aligns with the healthcare innovation landscape in Ireland, emphasizing the cross-border nature of the operation.
Industry
- Health Tech – Cumulus Neuroscience operates in the health tech industry, focusing on developing technologies for brain assessment and neurological treatment support.
- Biopharmaceuticals – The involvement with biopharma partners for drug development and treatment endorsement places the company within the biopharmaceutical industry.
Financials
- £3.25 million – Total investment raised in the funding round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Cumulus Neuroscience | Target | Company | A health tech company focusing on brain assessment technology. |
| Whiterock | Lead Investor | Company | Investment firm that led the funding round. |
| Investment Fund for Northern Ireland | Investor | Company | Provides investment capital and is managed by Clarendon. |
| Clarendon | Investment Manager | Company | Manages the Investment Fund for Northern Ireland. |
| ACF Investors | Investor | Company | Participant in the funding round. |
| Co-Fund NI | Investor | Company | Participant in the funding round. |
| Tina Sampath | Chief Executive | Person | CEO of Cumulus Neuroscience. |
| David McCurley | Investment Director | Person | Investment Director at Whiterock. |